Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUMP-IT: HAIP + Systemic Chemo for CRLM
NCT04552093Phase 3Unknown
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of floxuridine in colorectal liver metastases (CRLM), sponsored by Netherlands Cancer Institute. Primary endpoint: Completion of 2 combined chemotherapy cycles at 4 months. Status: unknown.
02
Drugs
floxuridine
03
Conditions
colorectal liver metastases (CRLM)
Beyond the preview
Go deeper on NCT04552093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04552093.